Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-26T20:09:04.754Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of the Cerebral Manifestations of Arteriosclerosis with Cyclandelate

Published online by Cambridge University Press:  29 January 2018

J. D. Young ,
Peter Hall  and
C. B. Blakemore
J. D. Young
Affiliation:
St. George's Hospital, Stafford
Peter Hall
Affiliation:
Powick Hospital, Powick, Nr. Worcester
C. B. Blakemore
Affiliation:
Cane Hill Hospital, Coulsdon, Surrey
Get access Rights & Permissions [Opens in a new window]

Extract

Despite controversy about whether cerebral arteriosclerosis is a valid clinical entity and independent of senile dementia and/or ‘functional’ senile psychoses (Post, 1971), there is a good reason for differentiating it in clinical practice, and its incidence is increasing (Registrar General, 1960).

Type
Research Article
Information
The British Journal of Psychiatry , Volume 124 , Issue 579 , February 1974 , pp. 177 - 180
Copyright
Copyright © Royal College of Psychiatrists, 1974 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allison, R. S. (1962). The Senile Brain. London: Arnold.Google Scholar
Ball, J. A. C., and Taylor, A. R. (1967). ‘Effects of cyclandelate on mental function and cerebral blood flow in elderly patients.’ British Medical Journal, iii, 525–8.CrossRefGoogle Scholar
Carter, A. Barham (1964). Cerebral Infarction. London: Pergamon.Google Scholar
Eichhorn, O. (1965). ‘The effects of cyclandelate on cerebral circulation.’ Vascular Diseases, 2, 6, 3–15.Google ScholarPubMed
Fine, E. W., Lewis, D., Villa-Landa, , and Blakemore, C. B. (1970). ‘The effect of cyclandelate on mental function in patients with arteriosclerotic brain disease.’ British Journal of Psychiatry, 117, 157–61.CrossRefGoogle ScholarPubMed
Fremont, R. E. (1964). ‘Clinical and Plethysmographic observations on the use of cyclandelate in arteriosclerosis.’ American Journal of Medical Sciences, 247, 2, 182–94.CrossRefGoogle ScholarPubMed
Hall, P., and Harcup, M. (1969). ‘A trial of lipotropic enzymes in arteriosclerotic dementia.’ Angiology, 20, 5, 287–300.CrossRefGoogle ScholarPubMed
Kuhn, R. A. (1966). ‘Effect of cyclandelate upon cerebral blood flow in patients with stroke.’ Angiology, 17, 422–6.CrossRefGoogle ScholarPubMed
Luisada, A. A., Jacobs, R., Bruce, D., Bernstein, J., and MacCanon, D. M. (1966). ‘Action of vasodilator on the circulation of the skull and brain.’ Vascular Diseases, 3, 201–7.Google ScholarPubMed
O'Brien, M. D., and Veall, N. (1966). ‘Effect of cyclandelate on cerebral cortex perfusion rates in cerebrovascular disease.’ Lancet, ii, 729–30.Google Scholar
Post, F. (1971). ‘The diagnostic process’, in Recent Developments in Psychogeriatrics (ed. Kay, D. W. K., and Walk, A.). British Journal of Psychiatry Special Publication No. 6.Google Scholar
Registrar General (1960). Census, England Cand Wales. London: H.M.S.O.Google Scholar
Smith, W. L., Lowrey, J. B., and Davis, J. S. (1968). ‘The effects of cyclandelate on psychological test performance in patients with cerebral vascular insufficiency.’ Current Therapeutic Research, 10, 613–18.Google ScholarPubMed
Stocker, G., Kuhn, R. A., Hall, P., Becker, G., and Van der Veen, E., (Ed.) (1971). Assessment in Cerebrovascular Insufficiency. Stuttgart: G. Thieme.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.